SynthesisRheumatology international2015
Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis.
Synthesis in Rheumatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 51 citations in OpenAlex.
- Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity.GeroScience · 2026Review
- Prevalence of comorbidities among patients with rheumatoid arthritis in the UAE: a case-control study.BMJ open · 2024Article
- Reversing the Inflammatory Process-25 Years of Tumor Necrosis Factor-α Inhibitors.Journal of clinical medicine · 2023Review
- Article
- Openreuma Consensus on the role of nursing in the care of patients with rheumatoid arthritis and diffuse interstitial lung disease.Investigacion y educacion en enfermeria · 2022Article
- Review
- Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases.ACR open rheumatology · 2021Review
- Management of Fibrosing Interstitial Lung Diseases.Advances in therapy · 2019Review
- Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.Clinical reviews in allergy & immunology · 2019Review
- Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.Annals of the rheumatic diseases · 2019Article
- [Characteristics of pharmacotherapy in older patients with rheumatism].Zeitschrift fur Rheumatologie · 2018Review
- Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study.BMC rheumatology · 2018Article
- Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study.Rheumatology international · 2016Article
- The challenging interplay between rheumatoid arthritis, ageing and comorbidities.BMC musculoskeletal disorders · 2016Review
- Comparison of the Charlson Comorbidity Index derived from self-report and medical record review in Asian patients with rheumatic diseases.Rheumatology international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study was to develop evidence-based and practical recommendations for the detection and management of comorbidity in patients with rheumatoid arthritis (RA) in daily practice. We used a modified RAND/UCLA methodology and systematic review (SR). The process map and specific recommendations, based on the SR, were established in discussion groups. A two round Delphi survey permitted (1) to prioritize the recommendations, (2) to refine them, and (3) to evaluate their agreement by a large group of users. The recommendations cover: (1) which comorbidities should be investigated in clinical practice at the first and following visits (including treatments, risk factors and patient's features that might interfere with RA management); (2) how and when should comorbidities and risk factors be investigated; (3) how to manage specific comorbidities, related or non-related to RA, including major adverse events of RA treatment, and to promote health (general and musculoskeletal health); and (4) specific recommendations to assure an integral care approach for RA patients with any comorbidity, such as health care models for chronic inflammatory patients, early arthritis units, relationships with primary care, specialized nursing care, and self-management. These recommendations are intended to guide rheumatologists, patients, and other stakeholders, on the early diagnosis and management of comorbidity in RA, in order to improve disease outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.